• Immunitrack will attend the LSX World Congress in London, 3-4 May 2023

Immunitrack will attend the LSX World Congress in London, 3-4 May 2023

This entry was posted on April 24, 2023 by Immunitrack.

Immunitrack’s CEO Stephan Thorgrimsen and chairman Karin Absalonsen will be participating in the LSX World Congress in London to connect with life science executives and investors.

About the LSX World Congress

The 9th LSX World Congress is the leading partnering, strategy, and investment event in Europe, with qualified 1:1 partnering at its core. The event brings together the CEOs and senior decision-makers from the world’s most innovative biopharma, med-tech, and health-tech companies with investors, senior BD&L teams, R&D leaders, and industry KOLs. Together they aim to create the world’s future medicines and improve patient outcomes. The congress represents the breadth, depth, and convergence of cutting-edge research and technology driving advances in the healthcare industry.

Read more about the event here ▸

If you would like to speak with Stephan or Karin at the event, please contact us using our contact form or email info@immunitrack.com to arrange an informal meeting.

About Immunitrack

The overall vision of Immunitrack is to enable better patient care through improved immunotherapy. Our mission is to advance the most reliable platform for predicting and validating T cell epitopes.

Our NeoScreen platform technology and T cell ID platform enable rapid and accurate immunogenicity screening and validation of potential T cell epitopes.

Read more about NeoScreen here ▸

Read more about T cell identification here ▸

Further, Immunitrack has established a platform to develop and characterize TCR-LA (T cell receptor-like antibodies). TCR-LA combines the TCR recognition mode with therapeutic efficacy and the versatility of conventional monoclonal antibodies.

Read more about TCR-LA here ▸

About us

Immunitrack’s mission is to provide the research community with tools to select or redesign drug candidates at the early stage of R&D but also to provide reagents to monitor lead drug candidates effect on patient’s immune system.

Contact

Immunitrack ApS
Lersø Parkallé 42
2100 Copenhagen Ø
CVR: 32347908

info@immunitrack.com
Tel. +45 28682159

Legal
Follow us